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Investigation of Mechanisms Underlying the T-Cell
Response to the Hapten 2,4-Dinitrochlorobenzene
Chris Pickard1, Andrew M. Smith1, Hywel Cooper1, Ian Strickland2, John Jackson3, Eugene Healy1
and Peter S. Friedmann1
T-cell mediated contact sensitization by small molecular weight xenobiotics results in significant morbidity and
absences from work. To be recognized by T-cells, xenobiotics must act as haptens, becoming protein-bound. At
present, the requirement for processing and presentation of xenobiotics, the nature of the T-cell responses to
them and the mechanisms that confer individual susceptibility in humans are unclear. We have investigated the
T-cell response to the hapten 2,4-dinitrochlorobenzene (DNCB) which can sensitize all immunocompetent
people. Fourteen healthy adults were sensitized with DNCB; 11 demonstrated positive T-cell responses to the
chemical in vitro. Responding cells were of both CD4þ and CD8þ subsets, of Th1 and Tc1 phenotypes,
producing high levels of IFN-g and low levels of IL-10. DNCB-specific T-cell clones were raised from 2 subjects,
which in the presence of fixed and unfixed autologous Epstein–Barr virus transformed B cells as antigen-
presenting-cells (APC), demonstrated that the chemical requires metabolic processing by the APC in order to
initiate the T-cell response. Intracellular-reduced glutathione is consumed in detoxication of DNCB, leaving
residual non-detoxified DNCB free to bind to proteins. The results suggest that DNCB forms multiple haptens
with intracellular and extracellular proteins leading to Th1 and Tc1 responses in individuals exposed to this
compound.
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INTRODUCTION
Contact sensitization involves the reaction of specific T cells
with causally relevant small molecular weight environmental
xenobiotics. The clinical consequences of allergic contact
dermatitis result in great morbidity with loss of time from
work. Several fundamental aspects of the immune response
to small xenobiotic molecules remain to be elucidated.
Firstly, these include the factors that make some individuals
susceptible to generating immune responses to xenobiotic
compounds that most individuals can encounter with no
apparent immunological consequences. Secondly, the me-
chanisms by which each small molecule become recogniz-
able by T cells are not clear. Thirdly, the nature of the
immune response itself in terms of T-cell effector and
regulatory mechanisms require further investigation.
In order for a small molecule or hapten to be recognizable
to T cells, it must become protein-bound. The sensitizing
potency of small molecules is generally reflected by their
chemical reactivity and ability to bind to nucleophiles/polar
molecules such as the e-amino group of lysine and the thiol
group of cysteine (Lepoittevin et al., 1995). Although it is
supposed that the hapten becomes conjugated to serum or
cellular proteins which can be processed and presented to
T cells in association with major histocompatibility complex
(MHC) molecules on the surface of antigen-presenting cells
(APC), very little is known about which proteins are the
carriers or the role of the APC in processing and presenting
these haptenated proteins. There is evidence that some
haptens can associate directly with the MHC–peptide
complex itself such that processing by the APC is not
required, for example, nickel binds directly to histidine
residues and trinitrophenyl binds to lysine residues in MHC-
bound peptides (Romagnoli et al., 1991; Moulon et al., 1995;
Weltzien et al., 1996). However, it would seem likely that
most haptens have to undergo intracellular metabolism-
dependent processing in order to become protein-bound and
MHC-associated and hence presentable to T cells (Anderson
et al., 1995). Indeed, it may be that differences in individual
susceptibility to sensitization by a xenobiotic reflect the
metabolic detoxication of the chemical, which, in susceptible
individuals, either fails to detoxify a reactive metabolite or
actively generates a protein-reactive, and hence potentially
immunogenic, hapten. 2,4-dinitrochlorobenzene (DNCB) is
useful for the study of mechanisms in contact sensitivity
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because it is able to induce contact sensitization in all
immunocompetent humans (Friedmann et al., 1983; Fried-
mann, 1991, 2006). It has been postulated that this is because
DNCB is already protein reactive and so does not require
metabolic bioactivation. Studies in mice have shown that the
immune response to DNCB involves both CD4þ and CD8þ
T-cell subsets expressing a Th1/Tc1 cytokine profile reflected
by high levels of IFN-g and little IL-4 and IL-10 (Dearman
et al., 1996). However, the immune response to DNCB in
humans has not yet been defined. In the present study, we
have investigated the nature of the human immune response
to DNCB. We have shown that, as in mice, DNCB is
recognized by T cells of both CD4þ and CD8þ Th1/
Tc1subtypes. In addition, the results demonstrate that the
presentation of DNCB in humans is mainly mediated
via metabolism-dependent processing. Furthermore, DNCB
associates with a great many cellular proteins in both the
cytoplasm and nucleus of human cells, an observation which
would explain the ability of DNCB to induce contact
hypersensitivity (CHS) in all immunocompetent individuals.
RESULTS
Clinical sensitization of volunteers
All the volunteers who received the initial sensitizing dose of
DNCB showed positive responses to epicutaneous challenge
with DNCB 4 weeks later. The median responses at each
challenge dose were: þ at 6.25 mg, þ þ at 8.8 and 12.5 mg
and þ þ þ at 17.7 mg. Peripheral blood mononuclear cell
(PBMC) were isolated from these volunteers at between 3 and
6 months after the elicitation challenge.
Both CD4þ and CD8þ T cells respond to DNCB
Culture of PBMCs with DNCB for 6 days resulted in
significant proliferative responses in 11 of the 14 sensitized
individuals tested. Peak responses occurred at DNCB
concentrations between 1 and 5 mM (Figure 1a). The median
(interquartile range) c.p.m. for unstimulated- and DNCB-
stimulated cultures were 411 (297–731) and 15,818
(3,153–23,607), respectively; median stimulation index (SI)
¼ 23.4, SEM¼6.5. No responses were observed when
PBMCs from non-sensitized individuals were cultured with
DNCB (n¼7; Figure 1a).
When CD4þ and CD8þ T cells were enriched by
depletion of the reciprocal T-lymphocyte subset, both
these subsets of T cells proliferated in response to DNCB
(Figure 1a). The responses of the enriched subsets to
streptokinase/streptodornase (SK/SD) were examined as a
control for a non-contact sensitizing protein antigen. In the
six individuals tested, proliferative responses to SK/SD were
found exclusively in the CD4þ enriched subset (P¼0.036;
Figure 1a).
These results were confirmed by labeling unfractionated
PBMCs with carboxyfluorescein diacetate succinimidyl ester
(CFSE). Results from four DNCB-sensitized individuals con-
firmed that both CD4þ and CD8þ T-cell subsets had
proliferated in response to DNCB after 6 days (Figure 1b).
This assay also confirmed that the cells responding to SK/SD
were almost exclusively CD4þ T cells (Figure 1b).
The responding T cells exhibit a Th1/Tc1 cytokine profile
Supernatants from CD4þ and CD8þ enriched T cells
cultured for 6 days in the presence and absence of DNCB
were assayed for production of various cytokines (N¼ 7).
Both CD4þ and CD8þ enriched T cells produced significant
quantities of IFN-g in response to DNCB (P¼0.03 and 0.003,
respectively; Table 1). Interestingly, production of IL-10
appeared to be actively suppressed in DNCB-containing
P = 0.009 P = 0.57 P = 0.036
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Figure 1. Both CD4þ and CD8þ T cell subsets from pre-sensitized
individuals respond to DNCB in vitro. (a) PBMC from non-sensitized normal
controls (NS; n¼ 7) and from DNCB-sensitized individuals (DNCB-S; n¼ 14),
were challenged with DNCB for 6 days in culture. CD4þ and CD8þ subsets
were depleted from the PBMC from eight sensitized individuals. The
reciprocal enriched subsets (E) were challenged with DNCB and SK/SD. Peak
responses are shown for each individual and the horizontal bar represents the
mean SI (b) Proliferation of both CD4þ and CD8þ subsets was confirmed
using the incorporation of CFSE. The filled histogram represents unchallenged
CFSE-stained PBMC from a representative pre-sensitized individual. The open
histogram represents DNCB challenged PBMC.
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cultures compared with DNCB-lacking controls (P¼0.02 and
P¼0.006, respectively for CD4þ and CD8þ subsets). There
was very little IL-5 and no detectable IL-4 release by the
DNCB-treated CD4þ and CD8þ subsets, with a nonsignifi-
cant increase above baseline in the absence of DNCB
(P¼0.3 and 0.05, respectively).
DNCB requires metabolic processing by viable APC
In order to determine the degree of metabolism required,
antigen-specific T-cell clones (TCCs) (n¼14) from two
DNCB pre-sensitized individuals were challenged with
DNCB-pulsed autologous, irradiated EBV-transformed B cells
(EBV-B) cells. The EBV-B cells were either fixed with
glutaraldehyde before antigen challenge, or left unfixed.
Fixation did not abrogate T-cell responses to EBV-B presented
toxic shock syndrome toxin-1 (Sigma UK; data not shown),
indicating that the fixation process did not disrupt the T-cell/
MHC synapse. After pulsing with DNCB for 12 hours, the
EBV-B cells were washed to remove unbound DNCB. The
response to DNCB was abrogated by prior fixation of the
EBV-B cells for each of the clones raised from one individual,
and for six of seven clones from the other individual.
However, one of the clones (TCC#1.5) from this latter
individual was able to respond to fixed DNCB pulsed EBV-
B cells with responses comparable to those observed with
non-fixed antigen-pulsed APC (Figure 2). Fixation of EBV-B
cells after pulsing with DNCB resulted in T-cell responses
similar to those observed in the presence of unfixed EBV-B
cells, providing further support that fixation does not interfere
with MHC-T-cell interaction (Figure S1).
DNCB binds to many intracellular/cellular proteins
PBMC from three individuals were incubated with DNCB for
increasing lengths of time (from 5 to 60 minutes) and stained
with an anti-dinitrophenyl fluorescein isothiocyanate-conju-
gated antibody, which recognizes the dinitrophenyl group
of DNCB. Cellular localization of DNCB was assessed by
confocal microscopy. Results from this analysis showed that
after as little as 5 minutes DNCB bound protein extensively
on the cell membrane and throughout the cytoplasm and
nucleus (Figure 3); the staining intensity at each of these sites
increased to a maximum at 1 hour. No staining was observed
in the untreated cells. In order to determine the number of
proteins associated with the chemical, PBMC isolated from
three individuals were incubated with 14C-labeled DNCB
and the cellular proteins were extracted and electrophoresed
through an SDS-PAGE-gel. This revealed multiple radio-
labeled bands suggesting that the DNCB was covalently
associated with a large number of proteins (Figure 4a). The
pattern of DNCB-labeled proteins generally mirrored the
pattern of staining with Coomassie blue in terms of band
intensity (Figure 4b). However, a predominant band, running
at approximately 75–80 kDa, was seen whereas a band of
Table 1. Cytokine production by DNCB challenged CD4+- and CD8+-enriched subsets
CD4+ enriched CD8+ enriched
Control DNCB Control DNCB
IFN-g 665.6 (60.7–1933.0) 3,499.0 (167.4–5000)* 444.0 (60.05–917.8) 4,181.0 (2,589.6–5,000)**
TNF-a 44.0 (24.05–217) 235.0 (87.3–798.8) 101.5 (71.2–167.3) 204.5 (69.1–538.5)
IL-2 3.1 (2.3–7.0) 10.6 (8.4–20.7) 1.2 (0–1.9) 6.3 (2.5–8.8)*
IL-5 1.3 (1.1–1.8) 9.5 (4.1–27.2) 1.8 (0–2.0) 7.3 (4.4–20.7)
IL-10 267.0 (91.9–517.8) 27.0 (21.2–60.2)* 427.4 (208.8–599.3) 32.0 (8.4–54.3)**
DNCB, 2,4-dinitrochlorobenzene.
All values=median pg/ml (interquartile range); n=7.
*Po0.05, **Po0.01.
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Figure 2. DNCB haptenation of cellular protein requires metabolic
processing by viable APCs. DNCB-specific TCCs from two individuals
(a and b) were challenged with both fixed and unfixed irradiated autologous
EBV-B cells that had been pulsed for 12 hours with DNCB. Histograms
represent the mean c.p.m. of triplicates, with error bars indicating the SEM.
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similar intensity was not observed on a Coomassie-stained
gel, suggesting that this does not represent an abundant
intracellular protein; preliminary attempts to isolate a single
protein from this band have been unsuccessful.
DNCB depletes intracellular glutathione
DNCB is detoxified by conjugation to intracellular gluta-
thione (GSH). We hypothesized that depletion of cytoplasmic
GSH would allow DNCB to bind to a greater extent to
intracellular proteins. To test this, we measured the intra-
cellular levels of GSH in PBMC incubated with 3 and 10 mm
DNCB and found that there was a dose- and time-dependent
depletion of GSH (Figure 5). Fifteen minutes after addition of
DNCB 3 and 10mm, the intracellular GSH levels had fallen to
79.5 and 55.2% of the baseline, respectively. After 60 min-
utes GSH levels had fallen to 42.4 and 20.0%, respectively,
the latter reaching statistical significance (P¼ 0.02). This
reduction in GSH over time correlated inversely with the
increase in intracellular DNCB protein binding seen with
confocal microscopy above. This reflects the use of GSH as a
co-substrate in the detoxication of DNCB and raised the
possibility that susceptibility to sensitization by DNCB is
determined by intracellular GSH reserves. Hence, depletion
of GSH with buthionine sulphoximine (BSO) (Griffith, 1982)
should increase the relative potency of a given concentration
of DNCB. This was examined by addition of BSO before
addition of DNCB. There was indeed a greater lymphocyte
proliferation response to each concentration of DNCB
(Figure 6): The mean SI elicited by DNCB was 8.372.6
(SE), N¼ 7; whereas after depletion of GSH it increased by
54% to a mean of 12.773.4; (Pp0.05 paired t-test). This was
specific for DNCB as there was no effect of BSO on the
responses of lymphocytes to a streptococcal-derived antigen
mixture (SK/SD).
DISCUSSION
CHS to small xenobiotic molecules is a common clinical
problem affecting large numbers of people, sometimes
requiring major changes in lifestyle. The nature of the
immune response and the reasons why in general, only
certain individuals develop such sensitivity, remain to be
elucidated. The sensitizing capacity of small molecular
weight chemicals is attributed to their ability to act as
haptens that, either as the parent compound or following
metabolic bioactivation, covalently modify protein nucleo-
philes (Smith Pease, 2003). The modified protein may then be
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Figure 3. DNCB binds extensively to intracellular protein. Adherent
monocytes were incubated with DNCB. Cells were fixed, permeabilized and
stained with a goat polyclonal anti-dinitrophenyl antibody and visualized at
100 original magnification. Green staining shows DNCB bound protein.
Blue shows nuclear staining. Inset shows non-DNCB-treated monocytes.
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Figure 4. DNCB binds to large number of intracellular proteins and to
the albumin component of human serum. (a) Total protein was extracted
from PBMC incubated with 14C-labeled DNCB for 12 hours, and run on a
SDS-PAGE gel. The resulting gel was exposed to X-ray film for seven days.
(b) Coomassie stain of total protein extracted from PBMC incubated
with DNCB. (c) 14C-DNCB-labeled human serum. (d) Coomassie stain
of human serum.
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Figure 5. DNCB depletes intracellular GSH. The reduced GSH content of
PMBC, pretreated with DNCB, was measured by HPLC. Data points show the
mean GSH intracellular content from three individuals, with error bars
indicating the SEM.
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processed and presented to CD4þ and/or CD8þ T cells in
the context of MHC class II and class I molecules,
respectively. Upon subsequent exposure to the chemical,
the recruitment and activation of memory T cells able
to recognize the hapten-modified protein results in the
local tissue inflammation characteristic of allergic contact
dermatitis.
There has been much controversy regarding the respective
roles of the CD4þ and CD8þ T cells in the development of
CHS to xenobiotics. In early work in mice it was shown that
both CD4þ and CD8þ T-cell subsets appeared to play a role
in the inflammatory response to DNCB, with both secreting
high concentrations of IFN-g and only low or undetectable
levels of IL-4 and IL-10 (Dearman et al., 1996). However,
more recent observations in murine systems investigating a
range of allergens suggest that the main effector cells in CHS
may be CD8þ cells with a Tc1 cytokine profile (high IFN-g)
(Martin et al., 2000, 2003) whilst the CD4þ T-cell subset may
have a regulatory function typified by a Th2 cytokine profile
(high IL-10 and IL-4 production) (Bour et al., 1995; Xu et al.,
1996; Desvignes et al., 2000). In humans allergic to nickel,
nickel-specific effector CD4þ and CD8þ T cells have been
identified (Cavani et al., 1998) but in nickel non-allergic
individuals an additional subset of CD4þ T cells producing
high amounts of IL-10 appear to inhibit the nickel-specific
response. More recently, punch biopsies taken from DNCB-
treated human skin revealed the presence of CD4þ
regulatory cells that produced high amounts of IL-10 and
IL-5 (Lecart et al., 2001). In our study, both CD4þ and CD8þ
subsets demonstrated a Th1/Tc1 phenotype, this finding
being more consistent with the earlier murine work carried
out by Dearman et al. (1996) In addition, the CD4þ response
to SK/SD in the absence of a CD8þ reaction confirms that the
combined human CD4þ and CD8þ response to DNCB was
particular to this antigen and not a nonspecific effect of
antigen-induced stimulation in our assay system. Moreover,
our results demonstrate that DNCB inhibits the production of
IL-10 by CD4þ and CD8þ subsets, which, through removing
immunoregulatory restraints by this cytokine, may account
for the ability of DNCB to sensitize all immunocompetent
subjects.
The question arises as to why and how both CD4þ and
CD8þ T-cell subsets are activated. Our results with confocal
microscopy and with 14C-DNCB show that DNCB binds
avidly to a wide range of intracellular proteins, and that
DNCB is also capable of binding to certain extracellular
proteins. The binding of DNCB to intracellular proteins
which are then processed via the MHC class I pathway would
activate CD8þ T cells. To activate CD4þ T cells, DNCB
bound to intracellular proteins from other cells (or extra-
cellular proteins such as serum proteins) may be cross-
presented by the APC via the MHC class II pathway. Our
results which showed that the stimulation of DNCB-specific
TCCs by DNCB-modified proteins was almost entirely
processing dependent (i.e., the APC required to be viable in
order to process and present the modified protein in the
context of MHC) are consistent with this. Alternatively,
DNCB may associate directly with peptides within the MHC
grooves of both MHC class I and II molecules, forming either
labile coordinate bonds as is the case with nickel, or by
covalently modifying peptides as is the case with trinitro-
phenyl. The latter has been shown to bind directly to lysine
e-amino groups of MHC embedded peptides in an intra-
cellular processing-independent manner (Weltzien et al.,
1996). Although only one of our CD4þ clones was able to
respond in a processing-independent manner, this suggests
that, as is the case with trinitrophenyl, DNCB may also bind
peptides that already reside within the MHC cleft. The
observation that dinitrophenyl modified proteins were also
localized on the cell surface on confocal microscopy (in
addition to extensive intracellular staining) would support
this conclusion. Furthermore, DNCB would appear to have
formed a strong association with surface proteins, as vigorous
washing of the DNCB-pulsed APC failed to abrogate the
subsequent lymphocyte response.
Classically, it has been thought that at physiological pH
DNCB binds predominantly to lysine residues of proteins
(Lepoittevin et al., 1995), although there is evidence to
suggest that it also binds efficiently to sulphydryl groups on
reduced GSH (Kato et al., 2003) and BSA (Parker et al.,
1983). GSH, the most prevalent non-protein thiol in animal
cells, plays a vital role in the detoxication of electrophilic
compounds, with the cysteine providing a nucleophilic
sulphydryl group to which the reactive chemical can bind
via the action of glutathione S-transferase (Townsend et al.,
2003). We have shown that DNCB depletes intracellular
levels of GSH and that this correlates inversely with increased
binding by DNCB to intracellular proteins (presumably
because the depletion of GSH leaves the excess DNCB free
to bind to nearby proteins). The corollary of this is that when
GSH was depleted by pretreatment with BSO, the given dose
of DNCB elicited stronger reactions presumably because less
was detoxified by conjugation to GSH. Furthermore, it has
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Figure 6. Depletion of intracellular GSH following treatment with BSO
increases the proliferative response to DNCB. PBMC from seven
DNCB-sensitized individuals were pretreated with BSO for 1 hour, and
then cultured for 6 days with DNCB. Peak responses are shown for each
individual and the horizontal bar represents the mean.
634 Journal of Investigative Dermatology (2007), Volume 127
C Pickard et al.
T-Cell Response to 2,4-Dinitrochlorobenzene
been shown that thiol containing anti-oxidants reduce CHS
responses (Becker et al., 2003; Bruchhausen et al., 2003;
Mizuashi et al., 2005). This also fits with the idea that DNCB
is detoxified by binding to GSH and other thiols so less is
available to evoke CHS responses.
The actual protein targets of electrophilic chemicals such
as DNCB are largely unknown. The observation that DNCB
binds extensively throughout the cytoplasm, nucleus and on
the cell membrane after as little as 5 minutes suggests that
DNCB is binding to a small number of ubiquitously expressed
proteins or that it is binding promiscuously to many proteins.
Using 14C-DNCB we were able to show that this chemical
binds to a large number of proteins as seen on the SDS-PAGE
gel. In contrast, the addition of 14C-DNCB to human serum
resulted in a dominant band running at approximately 66 kDa
corresponding to human albumin. This suggests that the
intracellular environment seems to favor protein binding by
DNCB, perhaps through active metabolic processes, and that
an unspecified number of these haptenated intracellular
proteins may form the antigenic moieties recognized by
CD8þ T cells. In addition, the results suggest that one of the
CD4þ antigenic targets is serum albumin and further support
for the existence of DNCB-serum protein antigen(s) comes
from our observations that human serum-DNCB conjugates
can stimulate a CD4þ DNCB-specific T-cell response (data
not shown). The role of serum albumin in mediating an
immune response to DNCB is also supported by a previous
finding by Johannesson et al., (2001) who showed that
occupational workers and guinea pigs exposed to the
sensitizing chemical hexahydrophthalic anhydride devel-
oped IgE and IgG antibodies against haptenated serum
albumin. Despite extensive binding to intracellular proteins,
we did observe a dominant 14C-DNCB-labeled band on
the gel at approximately 75–80 kDa; at present the identity
of this protein (or proteins) is unknown and further research
will be required to determine if it represents one of the
immunodominant moieties.
In conclusion, we have characterized the nature of the
human T-cell response to DNCB and have shown that both
CD4þ and CD8þ cells (Th1 and Tc1) are involved. We
showed that metabolism-dependent processing of DNCB is
frequently required for presentation of DNCB to T cells, but
that processing independent presentation of DNCB can also
occur (1 TCC of 14). During metabolic processing of DNCB
by APCs, the cellular reserves of GSH are depleted, allowing
greater amounts of DNCB to interact with cellular proteins.
Furthermore, the suppression of IL-10 by DNCB raises the
possibility that DNCB is a potent sensitizer in most
individuals because it prevents IL-10-induced inhibition of
the immune response against this xenobiotic.
MATERIALS AND METHODS
Subjects and controls
Volunteers were recruited from the dermatology outpatient popula-
tion and staff in Southampton University Hospitals Trust. All
individuals gave signed informed consent and the study was
approved by the local research ethics committee in adherence with
the Declaration of Helsinki Principles. For investigations on DNCB
reactive subjects, volunteers were sensitized to this agent as per our
previous studies (Friedmann et al., 1990). Fourteen DNCB allergic
subjects were included in the study, of whom 8 were male and 6
were female; ages ranged from 23 to 58 (median 34) years. Non-
sensitized controls (n¼ 12) included eight males and four females,
with ages ranging from 24 to 42 (median 31) years.
Sensitization of volunteers with DNCB
Volunteers received an initial application of 38mg of DNCB (Sigma,
UK) dissolved in acetone (Sigma, UK) on a 1.1 cm diameter paper
disc (DNCB concentration 35.4 mg/cm2) held in place for 48 hours
on the upper arm with an aluminum patch test chamber (Finn
Chamber, Epitest Oy, Finland). Four weeks later, the degree
of sensitization was assessed by application of four epicutaneous
patch tests of 6.25, 8.8, 12.5, and 17.7 mg of DNCB on 8 mm
Finn chambers. The challenges were removed after 6 hours,
according to our previously described method, and read at 48 hours
(Friedmann et al., 1990). Reactions were scored according to
the International Contact Dermatitis Research Group system
(Calnan et al., 1976), where þ þ is a definite erythema with
palpable infiltration. A positive response (þ þ or greater) at or
below the 12.5mg challenge site was taken as definite evidence of
sensitization.
Lymphocyte culture media
The lymphocyte culture medium used in this study was Rosewell
Park Memorial Institute media 1640 with L-glutamine (Gibco-BRL
Life Technologies, Paisley, UK) supplemented with 5% human AB
serum (Sigma, UK), 1 mM sodium pyruvate and 100 U/ml penicillin
and 100mg/ml streptomycin (Gibco-BRL Life Technologies). For
culture of the EBV-B the human serum was replaced by 10% fetal
calf serum (Gibco-BRL Life Technologies).
Lymphocyte proliferation assays
PBMCs were isolated from venous blood by centrifugation through a
density cushion (Lymphoprep, Nycomed). After washing, cells were
cultured at 1.2 106 cells/ml in 24-well plates with 0–10 mM DNCB
(dissolved in DMSO (Sigma, UK)) at 371C with 5% CO2 for 6 days.
Lymphocyte proliferation was determined by addition of 1mCi/ml of
3H-thymidine (Amersham, UK) for the final 6 hours. The cells were
harvested and incorporated 3H-thymidine measured with a scintilla-
tion counter. The SI was calculated by subtracting the counts per
minute (c.p.m.) for untreated cells from those of antigen-treated cells
and dividing by the c.p.m. for untreated cells. An SI greater than two
was taken as significant.
Depletion of CD4þ or CD8þ cells
CD4þ and CD8þ subsets were removed from whole PBMCs using
magnetic microbeads (Miltenyi Biotech, Miltenyi Biotech Ltd,
Surrey, UK) to give populations enriched for CD8þ and CD4þ
cells, respectively. In all cases, the residual contamination by the
reciprocal subset was less than 2%. The enriched subsets were
adjusted to 1.2 106 cells/ml and cultured for 6 days with 3 mm
DNCB. Proliferative responses were determined by measuring
incorporation of 3H-thymidine as above. Culture supernatants were
collected and quantification of cytokines (IL-2, IL-4, IL-5, IL-10,
TNF-a, and IFN-g) was carried out using a flow-cytometric bead
array system (BD Biosciences, Oxford, UK).
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CFSE dilution assay
PBMC were adjusted to 1 106 cells per ml in Rosewell Park
Memorial Institute media and labeled with 5 mM carboxyfluorescein
diacetate succinimidyl ester (Molecular Probes, Eugene, OR) for
10 minutes at 371C. The cells were then washed twice in phosphate-
buffered saline, resuspended in culture medium and stimulated with
3mM DNCB for 6 days. As controls, parallel cultures were stimulated
with SK/SD (10/2.5 units/ml, Cyanamid Pharmaceuticals, UK) for
6 days or 1 mg/ml of phytohaemagglutinin (Sigma, UK) for 3 days.
The proliferative response of the CD4þ and CD8þ subsets was
determined by flow cytometry (described below).
Generation of DNCB-specific TCCs and EBV-B cell-lines
Freshly isolated PBMCs from two DNCB allergic donors were
cultured at 1.5 106 cells per well in the presence of DNCB (3 mM).
After 7 days, the cells were cultured with IL-2 before being
stimulated again with DNCB and the addition of irradiated
(3,000 Rad) autologous PBMC.
DNCB-specific clones were subsequently generated by limiting
dilution assay and expanded with phytohaemagglutinin (Sigma, UK)
and IL-2.
Autologous B cell-lines were immortalized with EBV by
incubation in supernatant from an EBV-producing marmoset cell
line B95-8 (kindly donated by Dr Di-Genova, Cancer Sciences,
University of Southampton, UK) as described previously (Moulon
et al., 1995).
Effects of fixation of APCs on antigen-induced proliferation of
TCCs
To examine the requirement for metabolic processing of DNCB by
APCs, the EBV-B were fixed either before or after exposure to DNCB
with glutaraldehyde (final concentration 0.05%) for 30 seconds at
room temperature. The reaction was stopped by addition of L-lysine
(final concentration 0.2 M) and the cells washed three times with
phosphate-buffered saline. Fixed and non-fixed EBV-B cells were
incubated with 2mM DNCB for 12 hours, then washed  2 in large
volumes of phosphate-buffered saline to remove excess DNCB. Also,
after pulsing with DNCB, EBV-B cells were fixed with glutaralde-
hyde as above. For the measurement of the antigen-specific
proliferation, 105 TCC were incubated with 5 104 irradiated
(6,000 rad) fixed or unfixed autologous EBV-B cells in a U-bottomed
96-well plate for 72 hours. Proliferation was determined by
measuring incorporation of 3H-thymidine as above.
Flow cytometry
Cells were stained with allophycocyanin-labeled anti-CD4 (Caltag-
Medsystems Ltd, Buckingham, UK) and phycoerythrin-labeled anti-
CD8 (Sigma, UK) mABs; cells were analyzed on a FACSCalibur flow
cytometer (Becton Dickinson, Plymouth, Devon, UK) and analysis
was performed using the CellquestTM software.
Confocal microscopy
PBMCs (106 cells/ml) were plated onto glass coverslips and treated
with DNCB (4mM) at various time points from 5 minutes to 24 hours.
The non-adherent fraction was removed and the adherent fraction
fixed with 4% paraformaldehyde before being permeabilized with
ice cold 100% methanol. The cells were incubated with a polyclonal
goat anti-dinitrophenyl antibody (Sigma, UK) (1:2,000) for 1 hour
followed by the addition of a fluorescein isothiocyanate-labeled
anti-goat secondary antibody (Sigma, UK) (1:500). The cells were
counter stained with the anti-nuclear probe Topro-3 (Molecular
Probes), and intracellular staining was detected using two-channel
microscopy at  100 original magnification on a Zeiss confocal laser
microscope.
Analysis of intracellular protein binding of DNCB
PBMC were incubated with 3mM of either 14C-labeled (Tocris
Cookson Ltd., 56mCi/mmol) or unlabeled DNCB overnight in
culture medium. Cells were recovered, washed twice in phos-
phate-buffered saline and lysed in 1% triton  100 (Sigma, UK)
containing protease inhibitor cocktail (CompleteTM Mini, Roche, UK).
Cellular protein (100 mg 14C DNCB treated, 30mg of DNCB treated)
and human serum-DNCB conjugate (15 mg) were run on a 10% SDS-
PAGE gel under reducing conditions, against a pre-stained protein
molecular weight standard (Kaleidoscope Standard, Bio-Rad, UK).
Radio-labeled gels were fixed in 1% glycerol, 10% methanol and
10% glacial acetic acid for half-an-hour, dried, and exposed to
autoradiograph film (X-OMAT AR film, Kodak, UK) at 801C for 1–2
weeks. Total protein stains were carried out using Coomassie
Brilliant Blue (Bio Rad, UK).
Effects of DNCB on intracellular levels of GSH
The reduced GSH content of PMBC, pretreated with DNCB, was
measured by HPLC with fluorescence detection using penicillamine
as an internal standard (Anderson, 1985). The GSH: penicillamine
peak area ratio was calculated and samples quantitated by
comparison to the area ratios of known GSH standards. Intracellular
GSH was depleted by addition of buthionine sulphoximine (final
concentration 200 mM) for 1 hour (Rouzer et al., 1982).
Statistical analysis
Statistical significance between groups was evaluated using an
unpaired, two-tailed Student’s t-test. Mean differences were con-
sidered significant when Pp0.05.
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SUPPLEMENTARY MATERIAL
Figure S1: Fixation of EBV-B cells with glutaraldehyde does not disrupt the
TCR-MHC synapse.
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